Weight Management

A holistic approach emphasizing lifestyle modifications is essential to maintain weight loss after and while stopping medication.

The findings suggest a potentially elevated risk of vision impairment with semaglutide (Ozempic, Wegovy; Novo Nordisk) use compared with other weight loss and diabetes medications.

Automated diagnosis verification offers a promising alternative for managing the use of GLP-1 medications.

Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.

The expanded discount program offers semaglutide for $499 per month for all eligible cash-paying customers.

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

Patients adhering to cagrilintide/semaglutide treatment experienced an average 15.7% weight loss.

A brief period of overeating ultra-processed, high-calorie snacks could lead to liver fat accumulation and temporary disruption of brain insulin action.

Pharmacies could still experience localized availability issues for semaglutide despite its removal from the drug shortage list.

New options for tirzepatide provide a transparent, out-of-pocket choice for patients by streamlining the supply chain and bypassing insurance.

Treatment with semaglutide yielded superior effects on drinking outcomes compared with existing therapies to reduce alcohol cravings.

Using central obesity measures provides more accurate estimates of the proportion of CRC cases attributable to excess weight compared to using BMI alone.

Donna Ryan explains why long-term treatment with GLP-1 medication is typically necessary to maintain weight loss benefits.

Pharmacists should emphasize the importance of medication adherence and lifestyle changes.

Treatment with 2.4 mg of semaglutide did not increase the risk of developing suicidal ideation or behavior compared with placebo.

Proper nutrition and awareness of potential side effects from GLP-1 medications are essential for patients undergoing treatment.

Donna Ryan discusses the landscape of GLP-1 medications and the lineup of indications that the drug class has received indications for in recent years.

The phase 1b/2a results show the potential of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist.

Donna Ryan, MD discusses GLP-1 medications and new developments on the horizon, while providing some best practices for patients initiating treatment, including important nutritional and lifestyle changes,

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

The Commission aims to provide information for clinical decision making, therapeutic interventions, and public health strategies.

Approximately 33.2% of patients who received semaglutide 7.2 mg achieved 25% or more weight loss after 72 weeks.

Recommendations help influence the rate of gastric emptying, improve compliance, and prevent interruption of weight loss for patients.

If finalized, the requirement would include readily available nutrition information, including saturated fat, sodium, and added sugar content.